In various anticancer therapy settings (see Table 1 and Anticancer Therapy Differently Shapes the DC-Dying Cancer Cells Interface), DCs interacting with dead/dying cancer cells (treated with non-immunogenic or low-immunogenic anticancer agents) may attain a semi-mature state, i.e., while they may present low/medium levels of cancer antigens yet they either lack co-stimulatory signals (e.g., CD86) or suitable immunostimulatory cytokines (e.g., IL-12) (6, 10, 28, 37). This evidence concerns the gene CD86 and cancer.